Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy

• Status: Terminated
• Trial end date: 2005-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being done to evaluate the safety, tolerability and satisfactory relief of tegaserod against dyspeptic symptoms in diabetic patients with symptoms of diabetic gastropathy.

• Phase: Phase 2

Details

• Lead Sponsor: Novartis
• Treatments: Tegaserod

Criteria

Inclusion Criteria:

• History of Type 1 or insulin-requiring Type 2 diabetes for at least 3 years

• GI symptoms for at least 2 months before entering study

Exclusion Criteria:

• Very high body weight

• Significant diarrhea

• Ulcers

Symptom severity score collected via diary Other protocol-defined inclusion/exclusion criteria may apply.